View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 29, 2017updated 01 Mar 2019 2:09pm

GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus

GSK’s human monoclonal antibody Benlysta (belimumab) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to treat adult patients with systemic lupus erythematosus (SLE), a chronic, incurable, autoimmune disease.

By Staff Writer

Image: A young woman with the typical “butterfly rash” found in lupus. Photo: courtesy of Doktorinternet via Wikipedia.

 

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

GSK’s human monoclonal antibody Benlysta (belimumab) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to treat adult patients with systemic lupus erythematosus (SLE), a chronic, incurable, autoimmune disease.

Indicated for patients who are inadequate responders to existing therapies, Benlysta is approved for use as an add-on therapy in autoantibody-positive SLE patients.

Benlysta will be available in two formulations, one as an injection for intravenous (IV) treatment and the other as an injection for subcutaneous (SC) use.

The drug is designed to selectively target and directly bind to B-lymphocyte stimulator (BLyS) to help reduce B-cells and decrease the immuno-inflammation observed in patients with the disease.

GSK Specialty Care head, senior vice-president Vlad Hogenhuis said: “Patients living with SLE have limited treatment choices available and may have to endure the associated side effects these can cause.

“SLE symptoms are broad, variable and unpredictable in their intensity, which means an individualised treatment approach is needed.

“Benlysta, in its IV form, has been used to treat thousands of patients worldwide.

“We can now provide an important new treatment option to physicians and SLE patients in Japan.”

“We can now provide an important new treatment option to physicians and SLE patients in Japan.”

SLE, which is the most common form of lupus, affects approximately 70% of an estimated five million people with lupus worldwide, with an estimated 60,000 registered patients in Japan.

The approval has been granted based on data from two pivotal Phase III studies, Northeast Asia IV study and the BLISS-SC study. Efficacy and safety data from two global BLISS-IV Phase III studies, BLISS-52 and BLISS-76, has also been used.

While Benlysta IV 10mg/kg is licensed for use in the US, EU, and more than 70 countries across the globe, the drug’s subcutaneous formulation is approved for use in the US and is under review or planned regulatory submissions in other countries.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology